



V I S H L E S H A K

Analyse. Create. Automate.

vishleshak.in

INDIA HOSPITAL CHAINS RESEARCH HANDBOOK

Comprehensive Equity Research | Valuation | Qualitative Analysis | Global Benchmarking

Apollo · Max · Narayana · Fortis · Medanta · Aster DM · KIMS

Research Date	15 May 2026
Stocks Covered	7 Listed Hospital Chains
Valuation Models	EV/EBITDA P/E EV/Bed ROCE DCF
Global Benchmarks	India Singapore Thailand China USA

Kamal Arora

CFA Level II Cleared | 14 Years of Financial Markets Experience

IMPORTANT DISCLAIMER: Research views in this document are independent research opinions for educational purposes only. Vishleshak and Kamal Arora are NOT SEBI Registered Investment Advisors. These views do not constitute investment advice or a recommendation to buy or sell any security. Past performance does not guarantee future returns. Please consult a SEBI Registered Investment Advisor before making any investment decision.

1. Executive Summary


India's listed hospital chains represent one of the most compelling structural investment opportunities in Indian equities. Backed by rising disease burden, increasing health insurance penetration, and a growing middle class, hospital chains have delivered 19-35% stock CAGR over five years — outperforming every major sector index.

Core thesis: India has only 0.5 hospital beds per 1,000 people versus 2.4 in Singapore, 4.6 in China, and 2.9 in the USA. Healthcare spend is just 3.8% of GDP versus 7% in China and 17% in the USA. This structural underpenetration, combined with 101 million diabetics, 220 million hypertension patients, and a rapidly expanding middle class creates a multi-decade demand runway that no regulatory or competitive risk can meaningfully offset.

Key Findings

- All 7 chains are profitable with positive EBITDA — a mature cash-generating sector, not speculative growth
- Narayana Hrudayalaya: **Best ROCE (27.1%)** + most reasonable valuation (**29.8x EV/EBITDA**) = strongest long-term risk-reward despite near-term margin pressure
- Max Healthcare: Most efficient operator at **₹2.84 cr ARPOB** but most expensive at **95x PE** — limits near-term upside
- Apollo Hospitals: Strongest ecosystem moat through pharmacy + diagnostics + digital — **50M+ users** on Apollo 24/7 — but fully priced
- Global context: Indian chains trade at **2-4x premium** to global peers on EV/EBITDA — partially justified by superior growth, partially excessive
- KIMS and Medanta: Most underfollowed with DCF upside of **20%+** — best ideas for patient investors

2. India Healthcare Sector — Structural Overview



2.1 The Scale of the Opportunity

- India's hospital market valued at over **USD 100 billion in 2024**, projected to grow at **12-15% CAGR** through 2030
- 101 million diabetics** — world's largest diabetic population. Each patient requires 4-6 hospital visits per year for complications management
- 220 million hypertension patients** — cardiac disease is the #1 cause of death in India, driving explosive demand for cardiac care
- 1.53 million new cancer cases per year** — oncology is the fastest-growing hospital revenue segment at **17% CAGR**
- Health insurance penetration rising from **12% in 2014 to 32% in 2024** — each insured patient is worth 3-4x an uninsured patient in hospital revenue terms

2.2 Why Private Hospital Chains Specifically

- Government hospitals are chronically underfunded — **0.7 doctors per 1,000 people** versus WHO recommendation of 1.0. AIIMS Delhi has a 6-month waiting list for non-emergency surgery
- Ayushman Bharat PMJAY covers **500 million Indians** for hospitalisation up to ₹5 lakh — but reimbursement rates are **30-50% below private rates**. Private chains cherry-pick high-complexity cases while maintaining premium pricing on private-pay procedures
- India performs cardiac bypass surgery at **₹2-3 lakh** versus **₹40-50 lakh in the USA** — creating a massive medical tourism opportunity for Apollo and Narayana

3. Valuation Methodology

Hospital chains require specialised valuation approaches. Six metrics are used in combination to triangulate fair value.

Metric	How it works	Benchmarks	How to use it
EV/EBITDA	Enterprise Value ÷ EBITDA. Primary metric for hospitals — capital structure neutral, not distorted by depreciation or debt.	India avg 47x Global 15-25x	Primary screening multiple. India premium vs global justified by growth rate differential.
P/E Ratio	Price ÷ EPS. Simple but distorted by depreciation, interest, and one-time items. High PE acceptable if earnings CAGR is high.	India avg 75x Global 15-35x	Use as secondary metric. Check PEG ratio (PE/earnings growth) for normalised comparison.
EV per Bed	Enterprise Value ÷ Operational Beds. Unique to hospital sector. Shows market price per bed — useful for expansion-stage chains.	India avg ₹1.2 cr/bed US ~\$2-3M/bed	Use for expansion-stage chains where earnings suppressed by new hospital ramp-up costs.
ARPOB	Avg Revenue Per Occupied Bed/year. Measures revenue quality and treatment mix. Rising ARPOB = premiumisation.	Max ₹2.84 cr Narayana ₹1.75 cr	Track trend over time. Combine with occupancy rate. Flat ARPOB = commoditisation risk.
ROCE	Return on Capital Employed = EBIT ÷ Capital Employed. Most important long-term metric for capital-intensive businesses.	Narayana 27.1% Sector avg 16.7%	Minimum 15% for investment-grade quality. Improving ROCE trajectory is the key buy signal.
DCF	Discounted Cash Flow: project 10yr free cash flows, discount at WACC. Most correct theoretically but sensitive to assumptions.	WACC 10-11% Terminal growth 5%	Use as fair value anchor. Run sensitivity table. Stock below DCF base case = margin of safety.

4. Comparative Scorecard — All 7 Chains


Part A — Operational Metrics

Company	Seg	Beds	CMP (₹)	EV/ EBITDA	P/E	EBITDA %	ROCE%	ARPOB(₹cr)
Apollo Hospitals	Large Cap	8,000	₹7,409	52.1x	83.4x	18%	14.2%	₹2.21
Max Healthcare	Large Cap	3,454	₹1,116	68.4x	95.2x	21%	22.8%	₹2.84
Narayana Hrudayalaya	Mid Cap	5,800	₹1,737	29.8x	33.5x	21%	27.1%	₹1.75
Fortis Healthcare	Large Cap	5,554	₹970	56.2x	64.6x	14%	10.4%	₹2.51
Global Health (Medanta)	Mid Cap	2,800	₹1,314	47.8x	59.7x	18%	15.8%	₹2.10
Aster DM Healthcare	Mid Cap	3,200	₹627	50.1x	90.0x	13.8%	8.2%	₹1.90
KIMS Hospitals	Mid Cap	2,400	₹596	45.2x	80.1x	20%	18.6%	₹2.05


Part B — Returns, Valuation and Research View

Company	DCF Value	Upside	5yr CAGR	FII Hold%	EV/Bed(₹cr)	View
Apollo Hospitals	₹8,200	+10.7%	+20.4%	44.2%	₹1.42	ACCUMULATE
Max Healthcare	₹1,050	-5.9%	+35.0%	51.8%	₹3.18	HOLD
Narayana Hrudayalaya	₹2,200	+26.8%	+25.0%	22.4%	₹0.68	ACCUMULATE
Fortis Healthcare	₹1,100	+13.4%	+18.0%	35.6%	₹1.24	ACCUMULATE
Global Health (Medanta)	₹1,580	+20.2%	+31.0%	28.4%	₹1.15	BUY
Aster DM Healthcare	₹770	+22.8%	+10.0%	18.2%	₹0.82	ACCUMULATE
KIMS Hospitals	₹720	+20.8%	+15.0%	12.6%	₹0.98	ACCUMULATE


Indian Listed Hospital Chains — Size and Scale



Operational Efficiency Metrics — FY2025



5. Relative Valuation Analysis



EV/EBITDA — The Primary Metric

- Narayana at **29.8x EV/EBITDA** is the standout — nearly **40% discount to sector average of 50x** despite best ROCE and improving margins
- Max Healthcare at **68.4x** is the most expensive — justified partly by superior execution but limits return potential
- KIMS at **45.2x** offers reasonable value for a high-margin (**20% EBITDA**), high-ROCE (**18.6%**) operator with minimal analyst coverage


EV per Bed — The Expansion Story Metric

- Max Healthcare at **₹3.18 cr per bed** reflects market confidence in its premium positioning and capital efficiency
- Narayana at **₹0.68 cr per bed** is dramatically cheaper — significant upside if its Tier 2 city expansion succeeds
- Aster DM at **₹0.82 cr per bed** offers cheapest expansion optionality — bet on margin improvement as new hospitals mature

6. DCF Valuation — Apollo & Narayana

DCF analysis performed for Apollo and Narayana — the two chains with longest listed history. Base case assumes 14% revenue CAGR, 10.5% WACC, and 5% terminal growth.

DCF Sensitivity Analysis — Apollo & Narayana




DCF Assumptions — Base Case

Assumption	Apollo Base	Narayana Base	Rationale
Revenue CAGR (10yr)	14%	16%	Apollo: established scale. Narayana: faster expansion phase into Tier 2 cities.
EBITDA Margin Target	21% by FY30	24% by FY30	Premiumisation and operating leverage as new hospitals mature beyond breakeven.
WACC	10.5%	11.0%	Risk-free rate 7% + beta-adjusted equity risk premium of 5-6% for healthcare sector.
Terminal Growth Rate	5.0%	5.5%	Long-term India nominal GDP growth proxy — conservative relative to sector growth.
DCF Fair Value	₹8,200	₹2,200	Base case. Narayana has 27% upside; Apollo has 10.7% upside at current prices.
Current Market Price	₹7,409	₹1,737	As of 15 May 2026.

Key DCF insight: Apollo is trading close to fair value — needs 15%+ earnings surprise to drive meaningful upside. Narayana has clear 27% DCF upside in base case and 60%+ in bull case (18% revenue CAGR, 9% WACC). Risk-reward strongly favours Narayana over Apollo at current prices — despite near-term margin pressure.

7. Global Peer Comparison




Country/Company	Region	EV/EBITDA	P/E	Beds/1000 pop	Health % GDP	Pvt sector %
India (Apollo)	South Asia	52.1x	83.4x	0.5	3.8%	30%
India (Narayana)	South Asia	29.8x	33.5x	0.5	3.8%	30%
Singapore (IHH)	SE Asia	18.4x	28.6x	2.4	4.5%	80%
Thailand (BDMS)	SE Asia	22.6x	35.2x	2.1	3.9%	65%
China (Aier Eye)	East Asia	45.2x	52.4x	4.6	7.0%	55%
USA (HCA)	N. America	9.8x	14.2x	2.9	17.2%	90%
Malaysia (IHH)	SE Asia	17.8x	26.4x	1.8	4.2%	60%

Key Global Insights

- India (Apollo) at **52x EV/EBITDA** vs USA (HCA) at **9.8x** — a 5x premium. Even accounting for India's superior growth, the justified premium should be 2-2.5x, not 5x
- India (Narayana) at **29.8x** is actually reasonably priced vs Singapore IHH at **18.4x** — Narayana grows at 16% vs IHH at 8%, justifying a ~2x premium. At 1.6x actual premium, Narayana is the one Indian hospital stock that looks fair on global benchmarks
- India has just **0.5 beds per 1,000 population** vs China's **4.6** and USA's **2.9**. For India to reach China's level, the country needs to add ~5 million additional beds — a ₹5-10 lakh crore capital investment opportunity for listed chains over 15-20 years
- China (Aier Eye) at **45.2x EV/EBITDA** shows that specialty hospital chains in high-growth emerging markets can sustain premium multiples for years — supporting the bull case for Indian hospital valuations

8. Competitive Moat Analysis



8.1 What Makes Hospital Chains Defensible

Brand and Doctor Trust

In Indian healthcare, patients follow doctors, not hospitals. But doctors follow brand — they prefer practicing at hospitals that attract the right patient mix, have the right equipment, and offer research opportunities. Apollo's 30+ year brand and Narayana's Dr Devi Shetty association create doctor networks that take decades to build and cannot be bought.

Accreditation Complexity

NABH accreditation is mandatory for insurance empanelment. JCI accreditation opens international patient flows. Achieving and maintaining both requires 2-3 years of operational preparation — a significant entry barrier that even well-funded new entrants cannot shortcut.

Apollo's Ecosystem — The Unique Differentiator

- Apollo Pharmacy: **6,000+ stores** generating **₹8,000+ cr revenue** — largest private pharmacy chain in India. Captures patients after discharge, creating lifelong revenue streams
- Apollo Diagnostics: **200+ labs** — captures patients before hospitalisation with preventive health checkups
- Apollo 24/7: **50 million+ registered users** — India's largest connected healthcare ecosystem. Digital layer creates switching costs no single-segment competitor can match

9. Qualitative Research — Indian Context

9.1 The Ayushman Bharat Paradox

The government's PMJAY scheme covers 500 million Indians for hospitalisation up to ₹5 lakh. On the surface this threatens private hospital pricing. In practice it has been net positive for three reasons.

- Volume amplification: PMJAY brings millions of new patients into formal healthcare for the first time. Many are then diagnosed with conditions requiring ongoing private care beyond PMJAY coverage
- Cherry-picking: Private chains accept PMJAY for procedures where government reimbursement covers costs while maintaining premium pricing for complex oncology, transplants, and elective procedures
- Brand building: Treating PMJAY patients creates patient relationships that later convert to private-pay — particularly relevant in Tier 2 cities where aspirational healthcare spending is rising rapidly

9.2 Medical Tourism — The Dollar Revenue Opportunity

- India received **750,000+ medical tourists in FY24** generating **USD 9 billion in revenue** — up from USD 3 billion in 2015
- Average medical tourist spends **4-5x** what a domestic private-pay patient spends on the same procedure
- Apollo and Narayana are the top two destinations, with significant patient inflows from Bangladesh, Sri Lanka, East Africa, and the Middle East
- The Cayman Islands Health City (Narayana's international flagship) performs cardiac surgery at **25% of US costs** for American patients — a USD revenue stream immune to Indian healthcare pricing regulations

9.3 Digital Health Integration

- Apollo 24/7 has **50 million+ registered users** — the largest health app in India. Revenue from telemedicine, medicine delivery, and diagnostics growing at **40%+ annually**
- The digital layer reduces patient acquisition cost from **₹2,000-3,000** per new patient to near-zero for digitally-acquired patients — a significant operating leverage benefit


9.4 The Affordability Paradox

The most counterintuitive aspect of Indian healthcare: private hospitals are expensive by Indian standards but growing fastest. The explanation is the rapid expansion of India's consuming class — households earning ₹5-15 lakh annually (250+ million people) who can afford private care for serious illness. As household income crosses ₹8-10 lakh, the shift to private hospitals for secondary and tertiary care becomes near-universal.

10. Risk Analysis

Risk Factor	Severity	Description and Mitigation Signal
NABH & Regulatory	HIGH	Accreditation is mandatory for insurance empanelment covering 40-60% of premium hospital revenue. Any quality failures or loss of accreditation immediately cuts off insurance revenue. Monitor accreditation status and adverse event news flow quarterly.
Doctor Attrition	HIGH	Senior specialists carry patient loyalty. If a key cardiac surgeon or oncologist leaves, 20-30% of that specialty's revenue can exit in 6 months. Look for long-term doctor contracts, equity sharing programmes, and Revenue Per Doctor Employed trends.
Insurance Pricing	MEDIUM	PMJAY reimburses at 30-50% below private rates. As government insurance expands, hospitals face pressure to accept lower rates. Track % revenue from government schemes vs private insurance vs self-pay — higher self-pay = better pricing power.
Expansion Risk	MEDIUM	New hospitals take 5-7 years to reach breakeven occupancy. Aggressive expansion suppresses profitability and raises debt. Look for chains where existing hospitals have 75%+ occupancy before adding new capacity.
Medical Negligence	MEDIUM	Consumer courts and NCDRC awarding larger compensation in medical negligence cases. One high-profile adverse event can materially impact stock price and patient flows. Check pending legal cases in annual reports.
Competition	LOW	Barriers to entry are high — land, capital, accreditation, doctor recruitment all take years. But PE-backed new entrants in Tier 2 cities can gradually erode market share in specific geographies. Geographic diversification reduces this risk.

11. Stock Performance



- Narayana has delivered the highest absolute returns — **₹100 invested at 2016 IPO has grown to ₹481** — a 4.8x return in 10 years
- Apollo has delivered steady compounding — **5-year CAGR of 20.35%**, remarkably consistent across both COVID and post-COVID periods
- Max Healthcare since 2020 relisting has delivered **35% CAGR** — highest among currently listed names but from a small base post restructuring
- Fortis has underperformed due to legacy governance issues pre-IHH acquisition. The turnaround is underway but the multiple still carries a governance discount

12. Individual Stock Research Profiles

12.1 Apollo Hospitals (NSE: APOLLOHOSP | Large Cap)

Key Metric	Value	vs Sector Avg	Signal
CMP / DCF Fair Value	₹7,409 / ₹8,200	+10.7% upside	Undervalued
Research View	ACCUMULATE	—	+10.7%
EV/EBITDA	52.1x	Sector avg 50x	In line
P/E Ratio	83.4x	Sector avg 75x	Moderate
EBITDA Margin	18%	Sector avg 18%	At/above avg
ROCE	14.2%	Sector avg 16.7%	Adequate
ARPOB	₹2.21 cr	Sector avg ₹2.12 cr	Adequate
5-yr Stock CAGR	+20.4%	Nifty 5yr ~15%	Strong outperformance
FII Holding	44.2%	Higher = better confidence	Strong institutional buy

Investment Thesis

India's largest hospital network with unique integrated ecosystem spanning 6,000+ pharmacy stores and diagnostics labs. Apollo 24/7 digital platform has 50M+ registered users. Premium positioning with strong international patient inflows from Middle East and South Asia. Pharmacy and diagnostics contribute 40%+ of revenue reducing pure hospital cyclicality.

Key Risks

Highest valuation at 83x PE — earnings disappointment will be punished severely. Large debt from capacity expansion. Doctor attrition risk. Pharmacy faces e-pharmacy competition from PharmEasy and Tata 1mg.

Research View: ACCUMULATE | DCF Upside: **+10.7%** | Accumulate on dips. Current price largely factors near-term growth. Better entry at 10-15% correction. Hold for 5+ year horizon.

12.2 Max Healthcare (NSE: MAXHEALTH | Large Cap)

Key Metric	Value	vs Sector Avg	Signal
CMP / DCF Fair Value	₹1,116 / ₹1,050	-5.9% upside	At/above fair value
Research View	HOLD	—	-5.9%
EV/EBITDA	68.4x	Sector avg 50x	Expensive
P/E Ratio	95.2x	Sector avg 75x	Expensive
EBITDA Margin	21%	Sector avg 18%	At/above avg
ROCE	22.8%	Sector avg 16.7%	Best-in-class
ARPOB	₹2.84 cr	Sector avg ₹2.12 cr	Premium
5-yr Stock CAGR	+35.0%	Nifty 5yr ~15%	Strong outperformance

Key Metric	Value	vs Sector Avg	Signal
FII Holding	51.8%	Higher = better confidence	Strong institutional buy

Investment Thesis

India's most efficient hospital chain — highest revenue per bed at ₹2.84 cr. Despite fewer beds than peers, market cap equals Apollo — the market correctly rewards efficiency. Strong North India brand dominance. IFC and global PE backing adds governance credibility.

Key Risks

Most expensive globally at 95x PE. DCF suggests stock is at or above fair value. North India concentration risk. Any regulatory action on hospital pricing disproportionately impacts Max given premium positioning.

Research View: HOLD | DCF Upside: **-5.9%** | Hold existing positions. Avoid fresh buying at current valuations. Wait for 15-20% correction for better risk-reward entry.

12.3 Narayana Hrudayalaya (NSE: NH | Mid Cap)

Key Metric	Value	vs Sector Avg	Signal
CMP / DCF Fair Value	₹1,737 / ₹2,200	+26.8% upside	Undervalued
Research View	ACCUMULATE	—	+26.8%
EV/EBITDA	29.8x	Sector avg 50x	Cheap vs peers
P/E Ratio	33.5x	Sector avg 75x	Reasonable
EBITDA Margin	21%	Sector avg 18%	At/above avg
ROCE	27.1%	Sector avg 16.7%	Best-in-class
ARPOB	₹1.75 cr	Sector avg ₹2.12 cr	Volume-led model
5-yr Stock CAGR	+25.0%	Nifty 5yr ~15%	Strong outperformance
FII Holding	22.4%	Higher = better confidence	Growing interest

Investment Thesis

Best ROCE at 27.1% — highest capital efficiency in sector. Factory model for cardiac surgery delivers world-class outcomes at fraction of US cost. Cayman Islands Health City generates high-margin dollar revenues. Cheapest valuation at 29.8x EV/EBITDA despite superior returns.

Key Risks

Near-term margin pressure: net profit declined 2.35% in Q1 FY26 despite 15.4% revenue growth. Management guided very low single-digit price increases amid wage inflation from new labour code. Analyst downgrades to Hold/Sell by multiple brokerages in early 2026. Short-term earnings visibility clouded.

Research View: ACCUMULATE | DCF Upside: **+26.8%** | Accumulate in tranches — not lump sum. Near-term pain creates medium-term opportunity. DCF upside of 27% intact for 3-year horizon. Long-term fundamentals unchanged.

12.4 Fortis Healthcare (NSE: FORTIS | Large Cap)

Key Metric	Value	vs Sector Avg	Signal
CMP / DCF Fair Value	₹970 / ₹1,100	+13.4% upside	Undervalued
Research View	ACCUMULATE	—	+13.4%
EV/EBITDA	56.2x	Sector avg 50x	In line
P/E Ratio	64.6x	Sector avg 75x	Moderate
EBITDA Margin	14%	Sector avg 18%	Below sector — expansion room
ROCE	10.4%	Sector avg 16.7%	Below cost of capital
ARPOB	₹2.51 cr	Sector avg ₹2.12 cr	Premium
5-yr Stock CAGR	+18.0%	Nifty 5yr ~15%	Moderate outperformance
FII Holding	35.6%	Higher = better confidence	Growing interest

Investment Thesis

IHH Healthcare ownership since 2018 brought turnaround and governance improvement. Revenue per bed of ₹2.51 cr is second only to Max. EBITDA margins improving from 12% in FY22 to 14% in FY25 — room to 18%+ which peers achieve. Strong brand in oncology and organ transplants.

Key Risks

Lowest ROCE at 10.4% — still recovering from pre-IHH era. EBITDA margins lag peers significantly. Historical governance overhang. High debt from legacy acquisitions being gradually paid down.

Research View: ACCUMULATE | DCF Upside: **+13.4%** | Turnaround story with margin expansion runway. Accumulate for 3-4 year play. Each 1% EBITDA margin improvement adds ~15% to earnings.

12.5 Global Health (Medanta) (NSE: MEDANTA | Mid Cap)

Key Metric	Value	vs Sector Avg	Signal
CMP / DCF Fair Value	₹1,314 / ₹1,580	+20.2% upside	Undervalued
Research View	BUY	—	+20.2%
EV/EBITDA	47.8x	Sector avg 50x	In line
P/E Ratio	59.7x	Sector avg 75x	Moderate
EBITDA Margin	18%	Sector avg 18%	At/above avg
ROCE	15.8%	Sector avg 16.7%	Adequate
ARPOB	₹2.10 cr	Sector avg ₹2.12 cr	Adequate
5-yr Stock CAGR	+31.0%	Nifty 5yr ~15%	Strong outperformance
FII Holding	28.4%	Higher = better confidence	Growing interest

Investment Thesis

Premium super-specialty positioning with Dr Naresh Trehan brand — strongest individual physician brand in India. Expanding to Lucknow, Patna, Ranchi — underserved markets. 18% EBITDA margins with expansion room. Underfollowed — only 12 analyst estimates vs 25+ for Apollo — creates discovery opportunity.

Key Risks

Key man risk concentrated around Dr Naresh Trehan. Expansion into Tier 2 cities untested for Medanta premium model. Competition from Apollo and Max intensifying in NCR.

Research View: BUY | DCF Upside: **+20.2%** | *Best risk-reward among BUY-rated names. DCF suggests 20% upside. Underfollowed status creates alpha opportunity for early investors.*

12.6 Aster DM Healthcare (NSE: ASTERDM | Mid Cap)

Key Metric	Value	vs Sector Avg	Signal
CMP / DCF Fair Value	₹627 / ₹770	+22.8% upside	Undervalued
Research View	ACCUMULATE	—	+22.8%
EV/EBITDA	50.1x	Sector avg 50x	In line
P/E Ratio	90.0x	Sector avg 75x	Expensive
EBITDA Margin	13.8%	Sector avg 18%	Below sector — expansion room
ROCE	8.2%	Sector avg 16.7%	Below cost of capital
ARPOB	₹1.90 cr	Sector avg ₹2.12 cr	Adequate
5-yr Stock CAGR	+10.0%	Nifty 5yr ~15%	Moderate outperformance
FII Holding	18.2%	Higher = better confidence	Early discovery stage

Investment Thesis

Post GCC hospital sale (2024), now a clean India-only play focused on South India — Kerala, Karnataka, Andhra Pradesh. South India has highest healthcare awareness and willingness to pay. Proceeds being deployed in capacity expansion. Lowest EBITDA margin at 13.8% — significant operating leverage as new hospitals ramp.

Key Risks

Lowest ROCE at 8.2% — highest capital intensity without commensurate returns yet. PE of 90x expensive given margin profile. Post-GCC management integration still settling.

Research View: ACCUMULATE | DCF Upside: **+22.8%** | *Accumulate for 2-3 year margin expansion story. New hospitals need time to mature and reach 18%+ EBITDA.*

12.7 KIMS Hospitals (NSE: KIMS | Mid Cap)

Key Metric	Value	vs Sector Avg	Signal
CMP / DCF Fair Value	₹596 / ₹720	+20.8% upside	Undervalued

Key Metric	Value	vs Sector Avg	Signal
Research View	ACCUMULATE	—	+20.8%
EV/EBITDA	45.2x	Sector avg 50x	In line
P/E Ratio	80.1x	Sector avg 75x	Moderate
EBITDA Margin	20%	Sector avg 18%	At/above avg
ROCE	18.6%	Sector avg 16.7%	Adequate
ARPOB	₹2.05 cr	Sector avg ₹2.12 cr	Adequate
5-yr Stock CAGR	+15.0%	Nifty 5yr ~15%	Moderate outperformance
FII Holding	12.6%	Higher = better confidence	Early discovery stage

Investment Thesis

Hidden gem — strong 20% EBITDA margin and 18.6% ROCE with minimal analyst coverage. Dominant in Andhra Pradesh and Telangana — high-income southern markets. Expanding to Tier 2 South India cities where large chains do not compete. Low FII ownership at 12.6% = early institutional discovery stage.

Key Risks

Smallest scale — limited bargaining power with insurers. Geographic concentration in AP and Telangana. Thin free float creates stock volatility. Limited management bandwidth.

Research View: ACCUMULATE | DCF Upside: **+20.8%** | *Best undiscovered compounder. Accumulate systematically. DCF suggests 21% upside. 3-5 year horizon.*

13. Research View Summary

Research View Summary — Indian Hospital Chains
(Educational Purposes Only — Not SEBI Registered Investment Advice)

Company	NSE	CMP	DCF Value	Segment	Research View	Thesis (Short)
Apollo Hospitals	APOLLOHOSP	₹7,409	₹8,200	Large Cap	ACCUMULATE	Ecosystem moat; pharmacy+diagnostics
Max Healthcare	MAXHEALTH	₹1,116	₹1,050	Large Cap	HOLD	Best efficiency; expensive at 95x PE
Narayana Hruday.	NH	₹1,737	₹2,200	Mid Cap	ACCUMULATE	Best ROCE; near-term margin pressure
Fortis Healthcare	FORTIS	₹970	₹1,100	Large Cap	ACCUMULATE	Turnaround; IHH parentage; improving
Global Health	MEDANTA	₹1,314	₹1,580	Mid Cap	BUY	Premium; underfollowed; 20% upside
Aster DM	ASTERDM	₹627	₹770	Mid Cap	ACCUMULATE	South India; GCC sale complete
KIMS Hospitals	KIMS	₹596	₹720	Mid Cap	ACCUMULATE	Hidden gem; strong ROCE; Tier 2

LEGAL DISCLAIMER: Research Views (Buy / Accumulate / Hold / Avoid) are independent opinions for educational and research purposes only. Vishleshak and Kamal Arora are NOT registered with SEBI as Investment Advisors. These views do not constitute financial advice, a solicitation to buy or sell securities, or a promise of future returns. DCF valuations are based on assumptions that may not materialise. Please consult a SEBI Registered Investment Advisor (RIA) before any investment decision. The author may or may not hold positions in stocks mentioned.

How to Read Research Views

- **BUY:** Stock offers >20% DCF upside with strong fundamental support. Suitable for 3-5 year horizon.
- **ACCUMULATE:** Stock offers 10-20% DCF upside. Buy in tranches on market dips — not lump sum.
- **HOLD:** Stock at or near DCF fair value. Existing investors hold; new investors wait for better entry.
- **AVOID:** Stock above DCF fair value or fundamental deterioration underway.

14. Glossary

- **EV/EBITDA:** Enterprise Value divided by Earnings Before Interest Tax Depreciation Amortisation. Primary valuation multiple for capital-intensive sectors like hospitals.
- **ARPOB:** Average Revenue Per Occupied Bed per year. Higher ARPOB = more complex or premium procedures.
- **ROCE:** Return on Capital Employed. Above 20% = excellent for a hospital chain. The single most important long-term metric.
- **NABH:** National Accreditation Board for Hospitals. Mandatory for insurance empanelment in India.

- JCI: Joint Commission International. Global accreditation required for attracting international medical tourists.
- Occupancy Rate: % of beds occupied on average. 70-75% = EBITDA breakeven. Above 80% = strong pricing power.
- PMJAY: Pradhan Mantri Jan Arogya Yojana. India's government health insurance covering 500 million people.
- Medical Tourism: Patients travelling from abroad for treatment. India's medical tourism market: USD 9 billion.
- Hub and Spoke: Hospital network model — large tertiary hospitals (hubs) surrounded by secondary hospitals (spokes) that refer complex cases to the hub.
- DCF: Discounted Cash Flow. Estimates fair value by discounting projected future free cash flows at WACC.
- WACC: Weighted Average Cost of Capital. The discount rate in DCF — blended cost of debt and equity financing.
- PEG Ratio: Price/Earnings to Growth ratio. PE divided by earnings growth rate. Below 1.0 = potentially undervalued on growth-adjusted basis.

— End of Research Handbook —

Kamal Arora | CFA Level II Cleared | 14 Years of Financial Markets Experience | vishleshak.in

© 2026 Vishleshak. All research for educational purposes only. Not SEBI registered investment advice.